Comparison of the New Cardioselective Beta-Blocker Nebivolol with Bisoprolol in Hypertension: The Nebivolol, Bisoprolol Multicenter Study (NEBIS)

I. Czuriga, Igor Riecansky, Juraj Bodnar, Tibor Fulop, Valeria Kruzsicz, Eva Kristof, I. Édes

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Objective: The aim of the present study was to evaluate the antihypertensive efficacy of the highly beta1-selective adrenergic antagonist nebivolol in comparison with bisoprolol in the treatment of mild to moderate essential hypertension. Methods: This multicenter, single-blind, randomized, parallel-group 16-week study involved a 4-week placebo run-in, followed by a 12-week treatment period (5 mg nebivolol or 5 mg bisoprolol). Patients (n = 273) eligible for the study had a sitting diastolic blood pressure (DBP) between 95 and 110 mm Hg and a systolic blood pressure (SBP) ≤180 mm Hg at the end of the placebo run-in period. The primary endpoint of the study was the percentage of responders achieving DBP normalization (≤90 mm Hg) or a DBP reduction of at least 10 mm Hg. Results: The baseline SBP and DBP were similar in the two groups. Both SBP and DBP decreased gradually and significantly upon treatment. The two treatments had similar effects on the mean change from the baseline for both DBP (nebivolol -15.7 ± 6.4 mm Hg vs. bisoprolol -16.0 ± 6.8 mm Hg) and SBP. A high proportion of responders was noted in both groups (nebivolol 92.0% vs. bisoprolol 89.6%) and there was no significant difference between the treatments. The overall number and incidence of spontaneously reported adverse events were slightly, but not significantly lower for nebivolol (8 events; 5.8%) than for bisoprolol (12 events; 8.9%). Conclusions: The findings of the present trial indicate that 5 mg nebivolol once daily is an effective antihypertensive agent. It can therefore be recommended as a useful alternative first-line treatment option for the management of patients with mild to moderate essential hypertension.

Original languageEnglish
Pages (from-to)257-263
Number of pages7
JournalCardiovascular Drugs and Therapy
Volume17
Issue number3
DOIs
Publication statusPublished - 2003

Fingerprint

Nebivolol
Bisoprolol
Multicenter Studies
Blood Pressure
Hypertension

Keywords

  • Beta-adrenergic receptor antagonist
  • Bisoprolol
  • Hypertension
  • Nebivolol

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Comparison of the New Cardioselective Beta-Blocker Nebivolol with Bisoprolol in Hypertension : The Nebivolol, Bisoprolol Multicenter Study (NEBIS). / Czuriga, I.; Riecansky, Igor; Bodnar, Juraj; Fulop, Tibor; Kruzsicz, Valeria; Kristof, Eva; Édes, I.

In: Cardiovascular Drugs and Therapy, Vol. 17, No. 3, 2003, p. 257-263.

Research output: Contribution to journalArticle

@article{d39e861ab71644c69a013a4bea53bafa,
title = "Comparison of the New Cardioselective Beta-Blocker Nebivolol with Bisoprolol in Hypertension: The Nebivolol, Bisoprolol Multicenter Study (NEBIS)",
abstract = "Objective: The aim of the present study was to evaluate the antihypertensive efficacy of the highly beta1-selective adrenergic antagonist nebivolol in comparison with bisoprolol in the treatment of mild to moderate essential hypertension. Methods: This multicenter, single-blind, randomized, parallel-group 16-week study involved a 4-week placebo run-in, followed by a 12-week treatment period (5 mg nebivolol or 5 mg bisoprolol). Patients (n = 273) eligible for the study had a sitting diastolic blood pressure (DBP) between 95 and 110 mm Hg and a systolic blood pressure (SBP) ≤180 mm Hg at the end of the placebo run-in period. The primary endpoint of the study was the percentage of responders achieving DBP normalization (≤90 mm Hg) or a DBP reduction of at least 10 mm Hg. Results: The baseline SBP and DBP were similar in the two groups. Both SBP and DBP decreased gradually and significantly upon treatment. The two treatments had similar effects on the mean change from the baseline for both DBP (nebivolol -15.7 ± 6.4 mm Hg vs. bisoprolol -16.0 ± 6.8 mm Hg) and SBP. A high proportion of responders was noted in both groups (nebivolol 92.0{\%} vs. bisoprolol 89.6{\%}) and there was no significant difference between the treatments. The overall number and incidence of spontaneously reported adverse events were slightly, but not significantly lower for nebivolol (8 events; 5.8{\%}) than for bisoprolol (12 events; 8.9{\%}). Conclusions: The findings of the present trial indicate that 5 mg nebivolol once daily is an effective antihypertensive agent. It can therefore be recommended as a useful alternative first-line treatment option for the management of patients with mild to moderate essential hypertension.",
keywords = "Beta-adrenergic receptor antagonist, Bisoprolol, Hypertension, Nebivolol",
author = "I. Czuriga and Igor Riecansky and Juraj Bodnar and Tibor Fulop and Valeria Kruzsicz and Eva Kristof and I. {\'E}des",
year = "2003",
doi = "10.1023/A:1026180325278",
language = "English",
volume = "17",
pages = "257--263",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Comparison of the New Cardioselective Beta-Blocker Nebivolol with Bisoprolol in Hypertension

T2 - The Nebivolol, Bisoprolol Multicenter Study (NEBIS)

AU - Czuriga, I.

AU - Riecansky, Igor

AU - Bodnar, Juraj

AU - Fulop, Tibor

AU - Kruzsicz, Valeria

AU - Kristof, Eva

AU - Édes, I.

PY - 2003

Y1 - 2003

N2 - Objective: The aim of the present study was to evaluate the antihypertensive efficacy of the highly beta1-selective adrenergic antagonist nebivolol in comparison with bisoprolol in the treatment of mild to moderate essential hypertension. Methods: This multicenter, single-blind, randomized, parallel-group 16-week study involved a 4-week placebo run-in, followed by a 12-week treatment period (5 mg nebivolol or 5 mg bisoprolol). Patients (n = 273) eligible for the study had a sitting diastolic blood pressure (DBP) between 95 and 110 mm Hg and a systolic blood pressure (SBP) ≤180 mm Hg at the end of the placebo run-in period. The primary endpoint of the study was the percentage of responders achieving DBP normalization (≤90 mm Hg) or a DBP reduction of at least 10 mm Hg. Results: The baseline SBP and DBP were similar in the two groups. Both SBP and DBP decreased gradually and significantly upon treatment. The two treatments had similar effects on the mean change from the baseline for both DBP (nebivolol -15.7 ± 6.4 mm Hg vs. bisoprolol -16.0 ± 6.8 mm Hg) and SBP. A high proportion of responders was noted in both groups (nebivolol 92.0% vs. bisoprolol 89.6%) and there was no significant difference between the treatments. The overall number and incidence of spontaneously reported adverse events were slightly, but not significantly lower for nebivolol (8 events; 5.8%) than for bisoprolol (12 events; 8.9%). Conclusions: The findings of the present trial indicate that 5 mg nebivolol once daily is an effective antihypertensive agent. It can therefore be recommended as a useful alternative first-line treatment option for the management of patients with mild to moderate essential hypertension.

AB - Objective: The aim of the present study was to evaluate the antihypertensive efficacy of the highly beta1-selective adrenergic antagonist nebivolol in comparison with bisoprolol in the treatment of mild to moderate essential hypertension. Methods: This multicenter, single-blind, randomized, parallel-group 16-week study involved a 4-week placebo run-in, followed by a 12-week treatment period (5 mg nebivolol or 5 mg bisoprolol). Patients (n = 273) eligible for the study had a sitting diastolic blood pressure (DBP) between 95 and 110 mm Hg and a systolic blood pressure (SBP) ≤180 mm Hg at the end of the placebo run-in period. The primary endpoint of the study was the percentage of responders achieving DBP normalization (≤90 mm Hg) or a DBP reduction of at least 10 mm Hg. Results: The baseline SBP and DBP were similar in the two groups. Both SBP and DBP decreased gradually and significantly upon treatment. The two treatments had similar effects on the mean change from the baseline for both DBP (nebivolol -15.7 ± 6.4 mm Hg vs. bisoprolol -16.0 ± 6.8 mm Hg) and SBP. A high proportion of responders was noted in both groups (nebivolol 92.0% vs. bisoprolol 89.6%) and there was no significant difference between the treatments. The overall number and incidence of spontaneously reported adverse events were slightly, but not significantly lower for nebivolol (8 events; 5.8%) than for bisoprolol (12 events; 8.9%). Conclusions: The findings of the present trial indicate that 5 mg nebivolol once daily is an effective antihypertensive agent. It can therefore be recommended as a useful alternative first-line treatment option for the management of patients with mild to moderate essential hypertension.

KW - Beta-adrenergic receptor antagonist

KW - Bisoprolol

KW - Hypertension

KW - Nebivolol

UR - http://www.scopus.com/inward/record.url?scp=0242468829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242468829&partnerID=8YFLogxK

U2 - 10.1023/A:1026180325278

DO - 10.1023/A:1026180325278

M3 - Article

C2 - 14574084

AN - SCOPUS:0242468829

VL - 17

SP - 257

EP - 263

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 3

ER -